Coalescent Cyclical Vomiting: A Manifestation of Narcotic Bowel Syndrome?

Shreyas Saligram1,2*, David J. Levinthal1 and Klaus Bielefeldt1

1Department of Gastroenterology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA
2Department of Interventional Gastroenterology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA

ABSTRACT

This illustrative case suggests mechanisms that may contribute to disease progression and complications in adults with Cyclical Vomiting Syndrome (CVS). Symptoms initially followed a characteristic pattern in the context of marijuana use and led to repeated hospitalizations. Escalating opioid use for pain control resulted in coalescence of the syndrome with more frequent and severe emetic episodes, ultimately complicated by an esophageal microperforation. While analgesic therapy may play an important role in management of acute exacerbations, ongoing use of narcotics may contribute to the development of refractory CVS. This association of disease progression with opiates suggests that coalescent CVS should be considered a foregut manifestation of narcotic bowel syndrome.

KEYWORDS: Cyclical vomiting syndrome; Coalescing attack; Opioids; Narcotic bowel syndrome.

CASE REPORT

A 35 year-old man presented with an acute exacerbation of chronic abdominal pain, Nausea and Vomiting (N&V). The pain was severe, unrelenting and affected the entire abdomen with an epicenter in the Left Lower Quadrant (LLQ). He also experienced vomiting every 15-20 minutes. After several episodes of emesis, he had noticed sharp and then continuing pain in the center of the chest.

He had a long history of sudden episodes of abdominal pain, starting at the age of twenty. Initially, he had suffered from a sudden onset of pain associated with nausea and vomiting with a frequency of more than 20 times per day. Typically, such episodes woke him up in the early morning hours, persisted for several hours and eventually led to dehydration, requiring emergency room visits and even repeated hospitalizations. He could often alleviate milder symptoms by taking hot showers or baths. Emetic episodes lasted for up to one week and were followed by prolonged asymptomatic periods. However, his symptoms gradually progressed. Eventually, he received chronic opioid therapy for the recurrent pain, which was associated with an even more significant rise in the frequency of exacerbations. He had previously been diagnosed as suffering from irritable bowel syndrome, anxiety and depression. During the 6 years prior to his current presentation, he had undergone more than 20 abdominal computerized tomographies and ten upper endoscopies, which had all shown varying degrees of esophagitis or occasional Mallory Weiss tears. Additional diagnostic studies had excluded pancreatic disease, hereditary angioedema, porphyria, gastroparesis, and small bowel or colonic disease.

His outpatient medications included buprenorphine and naloxone, hydromorphone as needed, dicyclomine, gabapentin and citalopram. He regularly smoked marijuana since his teenage years. His family history was negative for migraines or CVS.
On admission, he complained about severe pain, was normotensive, but tachycardic. The key physical examination findings were a dry oral mucosa, subcutaneous crepitus in neck and anterior chest and diffuse abdominal tenderness without guarding or rebound. He had evidence of dehydration with hemoglobin of 18 g/dl, hematocrit 54.1%, and a creatinine of 4.2 mg/dl with associated anion ion gap acidosis. Imaging studies demonstrated a pneumomediastinum (Figure 1) with subcutaneous emphysema. As an esophagram did not show a contrast leak, he was treated conservatively with intravenous fluids, antiemetics, analgesic agents, acid suppression and antibiotics. He recovered and was discharged with the diagnosis of coalescent CVS, complicated by an esophageal microperforation. His treatment goal was to taper and then completely discontinue opioids and to stop cannabinoid use. To blunt the expected autonomic response associated with withdrawal, he received clonidine and was switched from citalopram to a Tricyclic antidepressant (TCA).

**DISCUSSION**

This case highlights several key points that are important for patients and physicians who deal with CVS, an unexplained disorder first described in children but now increasingly recognized in adults. The patient’s esophageal perforation was a secondary complication of repetitive vomiting, which more commonly causes esophagitis or gastrointestinal bleeding due to Mallory Weiss tears. Even though the apparent microperforation of the esophagus is an extreme example, it still emphasizes the need to identify an underlying disorder rather than focusing exclusively on the important consequences of repetitive vomiting. While only seen in a subset of patients, the case also illustrates the fact that CVS can undergo a phenotypic switch from its classic, dichotomous patterns of emetic and asymptomatic phases to eventual coalescence of increasingly frequent attacks with chronic nausea and pain complicated by typical exacerbations. Only a detailed history revealed that the patient clearly met diagnostic criteria for CVS (Table 1) at the onset of his illness. The progression of his illness was associated with the introduction of chronic opioid use to control symptoms, a change that has been linked the development of refractory disease.

Diagnosing CVS remains a challenge, and many patients undergo repeated and typically negative diagnostic evaluations, or even surgical treatments, before the diagnosis is entertained. Tests do not only constitute a financial burden, but also come with a risk, for example due to cumulative radiation exposure with radiographic testing or the risk of repeated endoscopıc evaluations. The patient’s history also supports the need to recognize the strong association of cannabinoid use with the development of CVS, as cannabis use has been found to contribute to the development of CVS in about 50% of the patients.

Acutely, the patient improved with symptom-driven management strategy that largely relied on intravenous analgesics, antiemetics and fluids. However, long-term treatment of CVS with preventative strategies is essential to reduce the number of attacks. After recognizing the disease, physicians need to identify potential triggers, such as opioid and cannabinoid use, both of which contributed in the case described. With the emergence of dependence, discontinuation of opioids or cannabinoids will trigger withdrawal symptoms that mirror emetic episodes of CVS. Thus, a slower taper may be required to prevent withdrawal in these individuals. In addition, clonidine and TCAs should be considered to blunt to autonomic response associated with withdrawal. TCAs remain the treatment of choice as preventative therapy for patients with CVS. Should TCAs fail or be contraindicated, coenzyme Q10 or anticonvulsive drugs may be acceptable alternatives. Seen in a broader context, our observation suggests that coalescing CVS is a foregut manifestation of the narcotic bowel syndrome and will require a multidisciplinary approach to achieve long-term remission.

---

**Table 1: Criteria for CVS in adults and children.**

| Adults – ROME III Criteria | Children – NASPGHAN Guidelines |
|---------------------------|--------------------------------|
| 1. At least 5 attack in any interval, or a minimum of 3 attacks during a 6 month period. | 1. Stereotypical episodes of vomiting with: |
| 2. Episodic attacks of intense nausea and vomiting lasting 1 h-10 days and occurring at least 1 week apart. | a) Acute onset |
| 3. Stereotypical pattern and symptoms in the individual patient. | b) Duration <1 week |
| 4. Vomiting during attacks occurs at least 4 times/hour | 2. Three or more discrete episodes in the prior year. |
| 5. Asymptomatic intervals between emetic phases. | 3. Asymptomatic intervals between emetic phases. |
| Absence of other specific causes. | 4. Stereotypical episodes and symptoms in the prior year. |

*NASPGHAN: North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition*
CONFLICTS OF INTEREST

Authors have no conflicts of interest or financial disclosure to make.

CONSENT

No consent is required to our article publication.

REFERENCES

1. Fleisher DR, Gornowicz B, Adams K, et al. Cyclic vomiting syndrome in 41 adults: the illness, the patients, and problems of management. *BMC Medicine*. 2005; 3: 20. doi: 10.1186/1741-7015-3-20

2. Prakash C, Clouse RE. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. *Am J Gastroenterology*. 1999; 94: 2855-2860. doi: 10.1111/j.1572-0241.1999.01428.x

3. Hejazi RA, Lavenbarg TH, Foran P, McCallum RW. Who are the non-responders to standard treatment with tricyclic antidepressant agents for cyclic vomiting syndrome in adults? a large single center experience. *Alimentary Pharmacology & Therapeutics*. 2009; 31(2): 295-301. doi: 10.1111/j.1365-2036.2009.04165.x

4. Allen J, De Moore G, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. *Gut*. 2004; 53: 1566-1570. doi: 10.1136/gut.2003.036350

5. Saligram S, Bielefeldt K. Opioids and cyclical vomiting syndrome. *Gastroenterology*. 2011; 140(5): S805.

6. Saligram S, Bielefeldt K. The two sides of opioids in cyclical vomiting syndrome. *N Am J Med Sci*. 2014; 6(3): 114. doi: 10.4103/1947-2714.128472

7. Sontineni S, Chaudhary S, Sontineni V, et al. Cannabinoid hyperemesis syndrome: clinical diagnosis of an under recognised manifestation of chronic cannabis abuse. *World J Gastroenterol*. 2009; 15: 1264-1266. doi: 10.3748/wjg.v15.i15.1264

8. Abell, TL, Adams KA, Boles RG, et al. Cyclic vomiting syndrome in adults. *Neurogastroenterol Motil*. 2008; 20: 269-284.

9. Grunkemeier D, Cassara J, Dalton C, et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. *Clin Gastroenterol Hepatol*. 2007; 5: 1126-1139.

10. Clouse RE, Sayuk GS, Lustman PJ, Prakash C. Zonisamide or levetiracetam for adults with cyclic vomiting syndrome: a case series. *Clinical Gastroenterology and Hepatology*. 2007; 5(1): 44-48. doi: 10.1016/j.cgh.2006.10.004

11. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. *Gastroenterology*. 2006; 130: 1466-1479. doi: 10.1053/j.gastro.2005.11.059

12. Li BUK, Lefevre F, Chelninsky GG, et al. North American Society for pediatric gastroenterology, hepatology, and nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. *J Pediatr Gastroenterol Nutr*. 2008; 47: 379-393. doi: 10.1097/MPG.0b013e318173ed39